via UT Southwestern Medical Center
Eliminating a single gene can turn exhausted cancer-fighting immune cells known as CD8+ T cells back into refreshed soldiers that can continue to battle malignant tumors, a new study led by UT Southwestern researchers suggests. The findings, published online this week in the Journal for Immunotherapy of Cancer, could offer a new way to harness the body’s immune system to attack cancers.
In 2017, the Food and Drug Administration approved treatments involving chimeric antigen receptor T (CAR-T) cells, which consist of immune cells known as T cells that have been engineered to recognize specific proteins on the surface of cancer cells. When these cells are delivered by infusion, they mount a targeted immune response against cancer cells.
CAR-T cells have been successfully used to treat blood cancers such as leukemia and lymphoma, often with dramatic results, says Venuprasad Poojary, Ph.D., associate professor of internal medicine and immunology at UTSW. However, these treatments have had little success against solid tumors, such as those that develop in the colon, breast, and lung.
When CAR-T cells enter these solid tumors, Poojary explains, they quickly become dysfunctional and lose their cancer-fighting abilities. This state, referred to as “exhaustion,” is accompanied by the addition of proteins, including PD1 and Tim3 on their surfaces and an inability to produce their usual immune-inciting molecules, such as Interferon-gamma and tumor necrosis factor. Finding a way to prevent CAR-T cells from becoming exhausted has become a significant goal in cancer research, Poojary adds.
Toward this end, he and his colleagues scoured published research comparing gene activity in working and exhausted T cells. The researchers quickly zeroed in on a gene called Cbl-b, which is more active, or upregulated, in exhausted cells.
Poojary and his colleagues confirmed that Cbl-b was activated in T cells that infiltrated tumors in a mouse model of colon cancer. Not only did these cells lose their tumor-fighting abilities, but they also developed a characteristic set of cell surface proteins and inability to produce, or express, immune molecules characteristic of exhaustion. However, when the scientists used the gene editing tool CRISPR to delete Cbl-b in these cells, they regained their cancer-fighting capacity and lost other exhaustion features.
Adding evidence to Cbl-b’s key role in T cell exhaustion, the researchers used genetically altered mice in which this gene was shut down. When they transplanted cancer cells into these animals, the cells grew tumors markedly smaller than in cancer cells of mice with active Cbl-b.
Further experiments showed that removing Cbl-b also prevented exhaustion specifically in CAR-T cells, Poojary adds. When he and his team deleted this gene from CAR-T cells engineered to recognize carcinoembryonic antigen, a cell surface protein commonly overexpressed in colon cancer, the cells effectively fought cancer in mice bearing these tumors – significantly extending their survival. However, CAR-T cells with functioning Cbl-b quickly became useless, providing little anti-tumor effect in animal models.
Poojary and his colleagues are working to understand the molecular mechanisms behind how Cbl-b causes T cell exhaustion. Once researchers better understand this mechanism, he notes, using CAR-T cells to effectively treat solid tumors could be as simple as genetically engineering them without Cbl-b.
“Our study is a major step forward in developing CAR-T cells to fight solid tumors,” Poojary says. “This could overcome the limitations of some current immunotherapy strategies for cancer.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
CAR-T cells
- Astellas hitches a ride in Poseida's convertible for $50M cell therapy collaboration
Astellas is in the market for a new CAR, and Poseida Therapeutics has a shiny convertible just the right size. | Astellas is in the market for a new CAR, and Poseida Therapeutics has a shiny ...
- Cell Therapy Manufacturing: Time to Move Fast
The more quickly manufacturing and release obstructions can be cleared, the sooner lifesaving treatments can be administered.
- T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of ...
- Do cutting-edge CAR-T-cell therapies cause cancer? What the data say
Regulators have identified around 30 cases of cancer linked to this blockbuster treatment. But is CAR T to blame? The hunt is on for answers.
- CAR T-Cell Therapy Market to Reach Valuation of USD 22.2 Billion By 2032: Astute Analytica
Soaring blood cancer rates fuel the CAR-T cell therapy market, a personalized weapon against aggressive cancers. Despite high costs, research breakthroughs and growing approvals promise broader access ...
Go deeper with Google Headlines on:
CAR-T cells
[google_news title=”” keyword=”CAR-T cells” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Immunotherapy strategies for cancer
- New gene signature could transform immunotherapy for gastrointestinal cancers
Despite significant progress in treating gastrointestinal (GI) cancers through surgical resection, chemotherapy, radiotherapy, and targeted therapy, the objective response rate (ORR) for immune ...
- Unlocking the immune system: cGAS-STING pathway offers new hope for cancer treatment
Cancer immunotherapy, which leverages the body's immune system to target tumors, has emerged as a pivotal strategy in oncology. This paradigm shift from conventional treatments offers a more precise ...
- Unlocking the immune system: cGAS-STING pathway offers new hope for cancer breakthroughs
A groundbreaking study has recognized the cGAS-STING signaling pathway as a formidable ally in the immune system's battle against cancer. This ...
- Vitamin D may balance gut microbiome to give cancer immunotherapy a boost
A new study in mice found that dietary vitamin D plays a role in balancing the gut microbiome and improving the way cancer immunotherapy works to fight tumors.
- Immunotherapy Developed To Localize Cancer-Killing Molecules
A new immunotherapy has been developed that localizes cytokines to tumors for weeks while preserving their activity.
Go deeper with Google Headlines on:
Immunotherapy strategies for cancer
[google_news title=”” keyword=”immunotherapy strategies for cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]